Analytical Data
-
基因名
CCL11
- Application
-
别名
C-C motif chemokine 11 Eosinophil chemotactic protein Small-inducible cytokine A11
-
种属
Human
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P51671
-
表达区间
1-97aa
-
蛋白长度
Partial
-
分子量
35.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL11, also known as Eotaxin-1, is a crucial chemokine involved in the allergic and inflammatory response, particularly in the recruitment of eosinophils. Elevated levels of CCL11 have been associated with various allergic diseases, such as asthma, rhinitis, and atopic dermatitis. The interest in CCL11 research stems from its potential role as a therapeutic target, as blocking its activity might alleviate eosinophilic inflammation and related symptoms. Recombinant CCL11 proteins have been developed to study their biological functions, signaling pathways, and receptor interactions in vitro and in vivo. These studies facilitate a better understanding of the chemokine’s involvement in immune responses and its implications in disease pathology. Moreover, recombinant CCL11 is being explored for use in preclinical models to evaluate potential anti-inflammatory therapies or targeted drug delivery systems. The characterization of this protein can also provide insights into its structure-function relationships and pave the way for new interventions in allergic and inflammatory disorders, making it a significant focus in immunological and therapeutic research.
